NCT00688883 - Fludara (Oral) Phase II Study for Indolent Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

August 31, 2004

Study Completion Date

August 31, 2004

Conditions

Lymphoma

Interventions

DRUG

Fludarabine Phosphate (Fludara)

Patients received Fludarabine Phosphate orally for 5 consecutive days, followed by a 23-day observation period. Setting this as 1 treatment cycle, 6 cycles will be given.

Trial Locations (17)

464-8681

Nagoya

466-8560

Nagoya

277-8577

Kashiwa-shi

812-0033

Fukuoka

812-8582

Fukuoka

003-0006

Sapporo

673-8558

Akashi-shi

890-0064

Kagoshima

259-1193

Isehara-shi

602-0841

Kyoto

980-0872

Sendai

852-8523

Nagasaki

700-8558

Okayama

570-8540

Moriguchi-shi

431-3192

Hamamatsu

104-0045

Chuo-ku

160-8582

Shinjuku-ku

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY